Rani Therapeutics to Present Bioequivalent Oral Semaglutide Data at ObesityWeek 2025
Key Insights
Rani Therapeutics will present preclinical data showing oral semaglutide (RT-116 (search)) delivered via RaniPill capsule is bioequivalent to subcutaneous injections in dogs.
The study demonstrates that oral delivery through the RaniPill platform elicits similar weight loss effects compared to traditional injection methods.
The presentation will take place at ObesityWeek 2025 on November 6, 2025, showcasing the company's novel oral delivery technology for biologics.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) announced it will present preclinical data demonstrating bioequivalence between oral semaglutide delivered via its RaniPill capsule technology and traditional subcutaneous injections. The clinical-stage biotherapeutics company will showcase these findings at ObesityWeek 2025, taking place November 4-7, 2025 in Atlanta, Georgia.
Breakthrough in Oral Biologics Delivery
The study, titled "Oral Semaglutide (RT-116 (search)) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss," represents a significant advancement in oral delivery of biologics. The preclinical data shows that semaglutide administered through the RaniPill capsule achieves bioequivalence to subcutaneous injections while producing similar weight loss effects in canine models.
Kyle Horlen, DVM, VP of Nonclinical Development at Rani Therapeutics, will present the findings during a poster session on November 6, 2025, from 2:30 pm to 3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1.
RaniPill Technology Platform
The RaniPill capsule represents a novel, proprietary and patented platform technology designed to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani Therapeutics has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule technology.
The company focuses on advancing technologies to enable the development of orally administered biologics and drugs, addressing a significant unmet need in the delivery of complex therapeutic molecules that traditionally require injection.